First Hit Fwd Refs

End of Result Set

Generate Collection Print

L3: Entry 90 of 90 File: USPT Sep 8, 1981

DOCUMENT-IDENTIFIER: US 4288542 A
** See image for Certificate of Correction **
TITLE: Radioenzymatic assay of catecholamines

CLAIMS:

45. In a composition which comprises in combination catechol-O-methyl transferase, a cation of oxidation number +2 selected from the group consisting of magnesium, cobalt, and manganese, a compund which stabilizes the catechol-O-methyl transferase-catecholamine enzyme-substrate system which is selected from the group consisting of glutathione, dithiothreitol, ascorbic acid, sodium metabisulfite, mercaptoethanol and cysteine, a mammalian system selected from the group consisting of blood serum, plasma, and urine, the methyl donor S-adenosyl-L-methionine-(.sup.3 H) methyl, the transferase, cation, stabilizing compound and methyl donor present in such quantities that substantially all the epinephrine, norepinephrine, and dopamine present in the mammalian system are O-methylated; the improvement consisting of the presence of an amount of ethylene glycol bis(aminoethylether)-N,N'tetraacetic acid sufficient to remove transferase-inhibiting concentrations of calcium ions.

75. In a composition comprising in combination catechol-O-methyl transferase, magnesium, glutathione, S-adenosyl-L-methionine (.sup.3 H) methyl, a human blood serum or plasma sample, the transferase, magnesium, glutathione and methyl donor present in such quantities that substantially all the epinephrine, norepinephrine and dopamine present in the human blood serum or plasma are O-methylated; the improvement consisting of the presence of an amount of ethylene glycol bis (aminoethylether)-N,N'tetraacetic acid sufficient to remove transferase-inhibitting concentrations of calcium ions.

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, March 17, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND		
☐	L3	(glutathione same combination).clm.	90
☐	L2	glutathione same combination	1614
☐	L1	6586404.pn.	2

END OF SEARCH HISTORY

L3: Entry 89 of 90 File: USPT Feb 8, 1983

DOCUMENT-IDENTIFIER: US 4372874 A
TITLE: Stabilization of hydrolysis prone labile organic reagents in liquid media

CLAIMS:

14. The method of claim 1 in which the organic reagent is selected from the group consisting of dithiothreitol, dithioerythritol, N-acetyl cysteine, glutathione, mercaptoethanol, and combinations thereof, and the solvent is a polyol containing from 2 to 4 hydroxyl groups and from 4 to 10 carbon atoms.

36. The method of claim 24 in which the organic reagent is selected from the group consisting of dithiothreitol, dithioerythritol, N-acetyl cysteine, glutathione, mercaptoethanol and combinations thereof, and the solvent is a polyol containing from 2 to 4 hydroxyl groups and from 4 to 10 carbon atoms.

L3: Entry 42 of 90 File: USPT Dec 24, 2002

DOCUMENT-IDENTIFIER: US 6498147 B2
TITLE: Suppression of nuclear factor-.kappa.b dependent processes using oligonucleotides

CLAIMS:

12. The method of claim 7, wherein the antisense oligonucleotide is administered in combination with a glutathione precursor.

22. A pharmaceutical composition comprising the antisense oligonucleotide of claim 1, in combination with a glutathione precursor.

First Hit Fwd Refs

Generate Collection Print

L3: Entry 41 of 90 File: USPT Feb 4, 2003

US-PAT-NO: 6514955
DOCUMENT-IDENTIFIER: US 6514955 B1
** See image for Certificate of Correction **

TITLE: Multi-faceted method to repress reproduction of latent viruses in humans and animals

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Van Dyke; Knox	Morgantown	WV		

US-CL-CURRENT: 514/171; 514/198, 514/369, 514/374, 514/378, 514/561, 514/563

CLAIMS:

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. One of a pharmaceutical composition and kit comprising: (i) an agent in an amount effective to cause blood glutathione levels to increase, selected from the group consisting of glutathione, N-acetyl cysteine, 2-oxo-4 thiazolidine carboxylic acid, ebselen, oltipraz, L-cysteine, N-acetyl cysteine ethyl ester, N-acetyl cysteine methyl ester, cystamine, cysteamine, penicillamine, 2,3 dimercapto-1-propanol, L-2-oxothiazolidone-4-carboxylate, dimethyl maleate, glutathione ethyl ester, glutathione methyl esters, glutathione isopropyl ester, oxazolidone, and combinations thereof; (ii) an amount of one or more additional antioxidants at a dose higher than the recommended daily minimum requirement; and (iii) an NFKB induction inhibitor in an amount effective to inhibit nuclear factor kappa B, said NFKB induction inhibitor being selected from the group consisting of anti-inflammatory steroids and nonglucocorticoid lazaroids.

2. The composition or kit of claim 1 wherein said additional antioxidants comprise at least one member selected from the group consisting of a water-soluble antioxidant, a fat-soluble antioxidant, and combinations thereof.

3. The composition or kit of claim 2 wherein said additional antioxidant is a water-soluble antioxidant.

4. The composition or kit of claim 3 wherein said additional water-soluble antioxidant is Vitamin C.

5. The composition or kit of claim 2 wherein said additional antioxidant is at least one fat-soluble antioxidant.

6. The composition or kit of claim 5 wherein said fat-soluble antioxidant is selected from the group consisting of Vitamin E, Vitamin K, Vitamin A, and combinations thereof.

7. The composition or kit of claim 1 in which said agent which causes blood glutathione levels to increase is N-acetyl cysteine.

8. The composition or kit of claim 1 wherein said NFKB induction inhibitor comprises an anti-inflammatory steroid.

9. The composition or kit of claim 8 wherein said anti-inflammatory steroid is selected from the group consisting of predonsone, prednisolone, methyl prednisolone, dexamethasone, beta metasone dehydroepiahdrosterone, 9a-fluorocortisol, prednisone, aetiocholanolone, 2-methylcortisol, pregnanediol, dexycorticosterone, cortisone, hydrocortisone, 6a-methylprednisolone, triamcinolone, estrogen, and combinations thereof.

10. The composition or kit of claim 1 in which said NFKB induction inhibitor is methyl prednisolone.